Active surveillance does not impair quality of life in low-risk prostate cancer

Key clinical point: The use of active surveillance caused no decline in quality of life for men with low-risk prostate cancer.

Major finding: Quality of life scores did not change significantly when averaged over 7 years of active surveillance; the physical function subdomain score showed clinical importance but remained about reference values.

Study details: The data come from 348 prostate cancer patients enrolled in the PRIAS trial, a prospective, longitudinal study of men with low-risk prostate cancer.

Disclosures: The study was supported in part by the Finnish Cancer Foundation, and the Jane and Aatos Erkko Foundation. The researchers had no financial conflicts to disclose.

Source: Lokman U et al. Eur Urol Focus. 2021 Jul 6. doi: 10.1016/j.euf.2021.06.008.

Key clinical point: The use of active surveillance caused no decline in quality of life for men with low-risk prostate cancer.

Major finding: Quality of life scores did not change significantly when averaged over 7 years of active surveillance; the physical function subdomain score showed clinical importance but remained about reference values.

Study details: The data come from 348 prostate cancer patients enrolled in the PRIAS trial, a prospective, longitudinal study of men with low-risk prostate cancer.

Disclosures: The study was supported in part by the Finnish Cancer Foundation, and the Jane and Aatos Erkko Foundation. The researchers had no financial conflicts to disclose.

Source: Lokman U et al. Eur Urol Focus. 2021 Jul 6. doi: 10.1016/j.euf.2021.06.008.

Key clinical point: The use of active surveillance caused no decline in quality of life for men with low-risk prostate cancer.

Major finding: Quality of life scores did not change significantly when averaged over 7 years of active surveillance; the physical function subdomain score showed clinical importance but remained about reference values.

Study details: The data come from 348 prostate cancer patients enrolled in the PRIAS trial, a prospective, longitudinal study of men with low-risk prostate cancer.

Disclosures: The study was supported in part by the Finnish Cancer Foundation, and the Jane and Aatos Erkko Foundation. The researchers had no financial conflicts to disclose.

Source: Lokman U et al. Eur Urol Focus. 2021 Jul 6. doi: 10.1016/j.euf.2021.06.008.